OptimizeRx Corp — Director's Dealing 2022

Oct 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2022-10-03

Reporting Person: Besch Doug (Chief Product Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-03	Restricted Stock Units	$	A	9973	Acquired		Common Stock (9973.0)	Direct
2022-10-03	Stock Option	$15.04	A	19527	Acquired	2027-10-02	Common Stock (19527.0)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.

F2: The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date.

F3: The stock option vests in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date.